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with typical antipsychotics and risperidone orally disintegrating
tablets and highest with depot risperidone formulation. This
ﬁnding is consistent with the results reported in the CATIE study
where only 25–45% of patients continued on oral treatment after
one year. Retention on medication is an important aspect of
patient outcomes in schizophrenia; these data suggest that reten-
tion on depot risperidone may be improved compared to other
treatments.
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OBJECTIVE: To identify treatment patterns and illness charac-
teristics preceding the initiation of depot typical antipsychotics in
the treatment of schizophrenia patients who are non-adherent
with oral antipsychotic regimens. METHODS: Data were drawn
from a large, multi-site, 3-year prospective non-interventional
observational study of schizophrenia patients in the U.S, con-
ducted between July 1997 and September 2003. The analytical
sample included patients who—in the six months prior to
enrollment—were non-adherent with oral antipsychotics and
were not treated with depot antipsychotics (N = 314). Non-
adherent patients who were subsequently initiated on typical
depots during the 3-year follow-up were compared with patients
continuing therapy with only oral agents. Comparisons were
made on clinical, functional, and treatment variables assessed at
predetermined intervals with standard psychiatric measures, a
patient self-report questionnaire, and medical record informa-
tion. RESULTS: A small proportion of patients (12.4%) previ-
ously non-adherent with oral antipsychotics were subsequently
initiated on a depot therapy during the 3-year study. Compared
to patients treated with only oral antipsychotics, those subse-
quently initiated on a depot were signiﬁcantly more likely to be
hospitalized at depot initiation or during the previous six
months, were more likely to have recent legal involvement, illicit
drug use, and treatment with more antipsychotics during the 3
months prior to initiation. CONCLUSION: Despite prior non-
adherence with antipsychotic medication, only a small propor-
tion of non-adherent schizophrenia patients were initiated on
depot antipsychotics in this 3-year prospective study. Patients
who were subsequently initiated on depot had a distinct treat-
ment pattern and illness proﬁle preceding initiation of the depot
medication.
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OBJECTIVES: To assess the reporting and scientiﬁc quality of
meta-analyses (MAs) of randomized controlled trials (RCTs) as
treatments for anxiety disorders. METHODS: We searched
EMBASE, EBM Reviews, MEDLINE, Healthstar and IPA from
inception to August 2007. Search terms included: MA, RCTs,
anxiety, anxiolytic, anti-depressant/antidepressant and cognitive
therapy with no language restrictions. Titles and abstracts were
assessed by two reviewers independently. Criteria for full-text
retrieval included: MA, statistical pooling, anxiety disorder,
RCT, pharmacotherapy, cognitive therapy. RCTs examining
anxiety symptoms were excluded. A manual search of refer-
ences was performed. Quality was assessed independently by
two raters, using the Quality of Reporting of Meta-analyses
checklist (QUOROM) and the Overview Quality Assessment
Questionnaire (OQAQ). Kendall’s tau measured inter-rater reli-
ability with statistical signiﬁcance at P  0.05. Means and stan-
dard deviations described the overall quality. A time series
analysis was performed. RESULTS: In total, 136 titles and
abstracts were reviewed; 48 were retrieved, including six from
the manual search. Twelve were excluded (not pooled analyses,
inappropriate condition or treatment or were duplicates),
leaving 36 studies. Publication dates ranged from 1990–2007.
Agreement was high; tau = 0.856 (P < 0.05) for QUOROM and
0.865 (P < 0.05) for OQAQ. The mean overall QUOROM
score was 65% (SD = 18%). The ‘results’ category yielded the
lowest quality scores while the introductions and discussions
yielded the highest. The mean overall OQAQ score was 59%
(SD = 25%). Flaws in scientiﬁc quality were observed regard-
ing ‘avoidance of bias’ and ‘validity’ while most studies linked
the results to the primary objective appropriately. There was
a small, non-signiﬁcant increase in quality of MAs over the
years observed. CONCLUSIONS: Reporting and scientiﬁc
quality of MAs in anxiety were only fair. They were, however,
higher than those previously reported for depression and criti-
cal care.
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OBJECTIVE: To evaluate clinical and functioning outcomes of
risperidone long-acting injection (RLAI) treatment in patients
with schizophrenia enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) from Czech Republic
and Slovakia. METHODS: e-STAR is an international, long-
term, prospective, observational study of patients with schizo-
phrenia who commence RLAI treatment. Data are collected
retrospectively for one year and prospectively every three months
for two years. Clinical outcomes were measured by Clinical
Global Impression-Severity (CGI-S) scale and patient functioning
was assessed using Global Assessment of Functioning (GAF)
scale. This interim report is based on data from patients who
have completed their 18-month follow-up visit. RESULTS: To
date, a total of 1324 patients have been enrolled in e-STAR from
the Czech Republic and Slovakia; 296 patients with at least
18-months of data available (97.3% still on RLAI) were included
in this analysis. Of the 296 patients, 53.7% were male with a
mean age of 37.6  12.0 years and a mean time since diagnosis
of 9.6  9.0 years. Mean CGI-S score signiﬁcantly decreased
from 4.6 plusmn; 1.1 at baseline to 2.9  1.0 at 18 months
(p < 0.001). Proportion of patients with not ill/very mild/mild
illness increased from 13.5% to 75.6% and that of patients with
marked/severe/extremely severe decreased from 48.8% to
6.3% (p < 0.001) compared to baseline. Meanwhile, patient
global functioning has signiﬁcantly improved as the mean GAF
score increased signiﬁcantly from 49.9  15.2 at baseline to
73.8  14.5 at 18 months (p < 0.001). CONCLUSION: Signiﬁ-
cant improvements in disease severity and functioning from base-
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line were observed during 18-month treatment with risperidone
long-acting injection in patients with schizophrenia.
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OBJECTIVE: Olanzapine and clozapine are two atypical antip-
sychotics associated with high risk of developing diabetes melli-
tus. However, a head to head comparison between these two
medications is not available. The objective of our study is to
compare the risk of developing type II diabetes with the use of
olanzapine vs. clozapine. METHODS: The study was a retro-
spective, longitudinal cohort analysis using 2001 Georgia
Medicaid claims data. Patients who had psychosis (ICD-CM-9:
290.xx–299.xx) and had received at least one prescription of
olanzapine or clozapine from March through November were
identiﬁed. The two study groups were deﬁned as patients who
initiated new treatment episodes of olanzapine and clozapine
after a 60 days window free of these medications. Patients who
received diabetes diagnosis (ICD-CM-9: 250.x0–250.x2) or
antidiabetic prescriptions 60 days prior and 30 days post the
index date (the date of treatment initiation) were regarded as
having pre-existing diabetes and excluded from the study. Logis-
tic regression analysis was employed to assess the association
between newly developed diabetes mellitus and the use of
antipsychotics. Confounders such as age, gender, race, treatment
duration, use of other antipyschotics, use of beta blockers and
thiazide diuretics were included in the ﬁnal model. RESULTS:
Out of 18,373 patients with an antipsychotic prescription in
2001, 4934 patients were olanzapine users and 376 patients were
clozapine users. The incidence rate of type 2 diabetes was 1.05%
among olanzapine users and 0.21% among clozapine users. After
controlling the confounders, it was found that the risk of devel-
oping type 2 diabetes was signiﬁcantly less for olanzapine
users as compared to clozapine users (OR 0.346 [CI 0.18–0.67]).
CONCLUSION: Patients taking clozapine are associated with
greater risk of developing type II diabetes as compared to
patients taking olanzapine.
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OBJECTIVE: Since many antipsychotics are metabolized by
cytochrome P450 (CYP450) isoenzymes (1A2, 2D6, and 3A4),
we proposed to assess the risk of receiving potential drug-drug
interaction (DDI) pairs associated with the inhibition or induc-
tion of CYP450 isoenzymes. METHODS: Using the Ohio Med-
icaid claims database from January 1, 2001 to December 31,
2003, a total of 44,511 patients (18  age  65) with a schizo-
phrenia or bipolar disorder diagnosis and receiving at least one
study antipsychotic were selected for this study. Any clinically
signiﬁcant (moderate or severe) DDI pair was deﬁned to have
concomitant exposure if any of the days supply for an antipsy-
chotic prescription overlapped with the days supply of an
interacting medication by at least one day. Patients with schizo-
phrenia and bipolar disorder were analyzed separately. Multi-
variable logistic regression analysis was used to assess risk factors
associated with the receipt of a potential DDI pair. RESULTS: Of
the 44,511 study patients, potential DDI pairs were received by
12.1% (11.9% in schizophrenia, 12.9% in schizoaffective, and
11.8% in bipolar sub-cohorts) as same-day prescriptions dis-
pensed and by 24.5% (24.7% in schizophrenia, 26.5% in
schizoaffective, and 24.5% in bipolar sub-cohorts) as prescrip-
tions with at least a one-day overlap. The most frequent DDI
pairs were observed with olanzapine (45.0%), risperidone
(23.5%), and quetiapine (13.4%). A higher risk of receiving a
potential DDI pair was associated with being Caucasian(odds
ratio [OR] = 1.27, 95% conﬁdence interval [CI]: 1.21–1.34),
treatment duration over 12 months (OR = 1.13, 95% CI: 1.07–
1.19), depression (OR = 1.20, 95% CI: 1.14–1.27), impulse
control disorder (OR = 1.53, 95% CI: 1.30–1.79), diabetes mel-
litus (OR = 1.12, 95% CI: 1.05–1.20), cerebrovascular disease
(OR = 1.34, 95% CI: 1.13–1.59). CONCLUSION: The potential
drug-drug interactions should be considered when treating
patients with some antipsychotics, especially during the long-
term maintenance use. Patients with key psychiatric and medical
co-morbidities had a higher risk of receiving potential DDI pairs.
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OBJECTIVE: There is growing awareness of the increased preva-
lence of metabolic abnormalities in patients with schizophrenia.
Thus, the safety and tolerability of atypical antipsychotic (AAP)
medications are important considerations in the choice of agents
to treat severe mental illness. In a systematic review of the pub-
lished literature on AAPs, we explored differences in metabolic
effects between ziprasidone and olanzapine. METHODS: We
identiﬁed 300 published studies of AAPs in schizophrenia,
including head-to-head, placebo-controlled trials and observa-
tional studies. A meta-analysis was performed on the safety and
tolerability of ziprasidone and olanzapine in areas with sufﬁcient
data (i.e., at least three studies for each outcome). Studies were
included in meta-analyses if they provided sample size, mean
change, and measure of variance, or if they reported data to
allow for imputation of these values. We considered changes in
total cholesterol, triglycerides, body weight, QTc interval, and
discontinuation due to adverse events. RESULTS: Of 13 publi-
cations reporting a head-to-head comparison of ziprasidone vs.
olanzapine, four provided data useful for pooled analyses. When
compared to ziprasidone, olanzapine use was associated with
increased total cholesterol (mean difference 20.0 mg/dL [95%
CI 9.8 mg/dL, 30.2 mg/dL]), triglycerides (mean difference
66.6 mg/dL [95% CI 43.6 mg/dL, 89.7 mg/dL]), and body
weight (mean difference 4.97 kg [95% CI 4.1 kg, 5.8 kg]). Mean
daily doses ranged from 112.8 mg to 135.2 mg (ziprasidone) and
from 12.6 mg to 20.5 mg (olanzapine). Mean changes in the QTc
interval and rates of discontinuation due to adverse events were
similar for ziprasidone vs. olanzapine (studies not pooled). Limi-
tations of the study included heterogeneity across the head-to-
head trials: study durations ranged from 6 to 18 months.
CONCLUSION: These results point to clinically important and
statistically signiﬁcant advantages for ziprasidone in metabolic
safety compared with olanzapine. Ziprasidone’s effect on the
QTc interval and tolerability are similar to olanzapine.
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